ForteBio Launches New Dip and Read Anti-FLAG Biosensor to Facilitate Protein Research and Drug Development

Tue Feb 12, 2013 4:30pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130212:nBw126653a

PORT WASHINGTON, N.Y.--(Business Wire)--
ForteBio, a division of Pall Life Sciences and a leading supplier of label-free
technology that accelerates the development of biotherapeutic and pharmaceutical
products, today announced the launch of its new Dip and Read Anti-FLAG Biosensor
for use on the company`s Octet and BLItz instrumentation systems. The new
biosensor enables researchers to quickly and easily detect FLAG-tagged
recombinant proteins for their quantitation and kinetic characterization, which
are key steps in drug development.

http://mms.businesswire.com/bwapps/mediaserver/ViewMedia?mgid=357970&vid=4
The Dip and Read(TM) Anti-FLAG Biosensor for use on ForteBio's Octet(R) and
BLItz(TM) instrumentation systems enables researchers to quickly and easily
detect FLAG-tagged recombinant proteins for their quantitation and kinetic
characterization.

"FLAG is a commonly used affinity peptide tag to enable protein detection and
purification," said Christopher Silva, vice president of marketing for Pall's
ForteBio division. "However, traditional methods for evaluating FLAG-tagged
proteins rely on time-consuming, analytical methods, which can slow down drug
discovery and development. Our new Anti-FLAG Biosensor, together with the BLItz
instrument platform`s ease of use or the Octet system`s high throughput, is
designed to greatly accelerate laboratory workflow, reduce time to results and
increase cost-efficiency." 

The biosensor is pre-immobilized with Sigma-Aldrich`s well-established,
high-affinity ANTI-FLAG M2 antibody, which has been cited in more than 30,000
journal articles over the last two decades. The high specificity of the
antibody-based biosensor enables the direct quantitation of FLAG-tagged analytes
in crude lysates, column eluents, cell lysates and cell culture supernatants. 

Mr. Silva added that the new biosensor is intended to address strong demand for
direct capture of FLAG-tagged proteins among ForteBio`s Octet customers. It also
should further broaden the appeal of the BLItz instrument platform - which
enables label-free analysis of proteins using small sample volumes on a benchtop
instrument - among academic researchers. "We are now pleased to offer our
customers biosensors for the three most widely used peptide tags - HIS, GST and
FLAG - among pharmaceutical and biotechnology scientists." 

The Octet family of products is based on ForteBio`s proprietary Bio-Layer
Interferometry (BLI) technology. These instruments incorporate disposable
optical Dip and Read biosensors that measure multiple interactions in parallel,
without the use of detection agents. For single-sample analysis, ForteBio
recently launched its BLItz instrument platform. The new platform revolutionizes
the use of label-free protein analysis by making it more accessible and
cost-effective for individual bench scientists in biotherapeutic discovery,
process development and academic research. 

About ForteBio

ForteBio is a division of Pall Life Sciences. ForteBio provides analytical
systems to accelerate biotherapeutic drug discovery and development. These
systems enable real-time, label-free analysis of biomolecular interactions,
providing information on affinity, kinetics and concentration. ForteBio`s
analytical capabilities enable significantly easier, faster and better
characterization of drug candidates, thus providing greater value in drug
development applications where existing methods have limitations in throughput,
performance and cost. For more information, visit www.fortebio.com. 

About Pall Life Sciences

Pall Life Sciences, a division of Pall Corporation (NYSE:PLL), provides
cutting-edge products and services to meet the demanding needs of customers
discovering, developing and producing biotech drugs, vaccines and classic
pharmaceuticals. Its membranes and membrane devices optimize detection and
sample preparation in the drug research, clinical diagnostics, genomics, and
proteomics markets. Pall Life Sciences is a leading provider of separation
systems and single-use filtration and purification technologies to
pharmaceutical and biotechnology companies to support faster development of new
drugs and vaccines that are safer and require less energy and water to produce.
Pall Life Sciences` technologies are also used in clinical institutions and the
food and beverage industries. 

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader
providing solutions to meet the critical fluid management needs of customers
across the broad spectrum of life sciences and industry. Pall works with
customers to advance health, safety and environmentally responsible
technologies. The company`s engineered products enable process and product
innovation and minimize emissions and waste. Pall Corporation is an S&P 500
company serving customers worldwide. Pall has been named a "top green company"
by Newsweek magazine. To see how Pall is helping enable a greener, safer, more
sustainable future, follow us on Twitter @PallCorporation or visit
www.pall.com/green.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130212006653/en/

Doug Novarro
Corporate Public Relations, Pall Corporation
516-801-9944
Doug_novarro@pall.com
or
Gemma Milan
ForteBio
650-289-6800
Gemma_milan@pall.com



Copyright Business Wire 2013